Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Delayed Nasdaq
Other stock markets
 10:53:55 2024-04-24 am EDT 		5-day change 1st Jan Change
2.44 USD +5.16% Intraday chart for VYNE Therapeutics Inc. +1.65% +4.70%
Apr. 04 Transcript : VYNE Therapeutics Inc. - Special Call
Feb. 29 VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
VYNE THERAPEUTICS INC. Stock VYNE Therapeutics Inc.
+4.70% 32.71M
C-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.51% 672B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.86% 570B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.21% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.59% 321B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.49% 300B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.98% 217B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-9.20% 204B
A+
NOVARTIS AG Stock Novartis AG
+5.17% 199B
B-
PFIZER, INC. Stock Pfizer, Inc.
-9.14% 149B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. Ratings VYNE Therapeutics Inc.